Business Context and Reporting Period
This Form 8-K was filed by Supernus Pharmaceuticals, Inc. on February 22, 2019. The filing primarily serves to announce modifications to executive compensation effective January 1, 2019, and to reference a press release (Exhibit 99.1) regarding financial results for the fourth quarter and full year ended December 31, 2018, which was issued on February 26, 2019.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These metrics are contained within the referenced press release (Exhibit 99.1) and are not detailed in the body of this 8-K report.
Material Changes and Executive Compensation
The Compensation Committee approved modifications to the compensation of four executive officers, effective January 1, 2019. The changes include base salary increases, 2018 bonuses, and stock option grants:
- Jack A. Khattar (CEO): Base salary increased from $724,000 to $812,000. Received a $635,000 bonus for 2018 and options to purchase 300,000 shares.
- Gregory S. Patrick (CFO): Base salary increased from $362,000 to $383,000. Received a $158,000 bonus for 2018 and options to purchase 40,000 shares.
- Stefan K.F. Schwabe (CMO): Base salary increased from $390,000 to $401,000. Received a $163,000 bonus for 2018 and options to purchase 40,000 shares.
- Padmanabh P. Bhatt (CSO): Base salary increased from $369,000 to $380,000. Received a $140,000 bonus for 2018 and options to purchase 35,000 shares.
Stock options for all officers have an exercise price of $36.75 per share and vest annually in equal increments over four years.
Guidance, Outlook, and Risks
The filing contains forward-looking statements regarding the company's plans and strategies but does not provide specific financial guidance or outlook figures in the text. It explicitly disclaims any obligation to update these statements. The document references risk factors detailed in the Company's 2017 Form 10-K and the Q1 2018 Form 10-Q, noting that forward-looking statements are subject to uncertainties inherent in the pharmaceutical industry and general economic conditions.
Investor Verification Checklist
- Review the attached Exhibit 99.1 (Press Release dated February 26, 2019) for specific Q4 and full-year 2018 financial results, as they are not included in this 8-K text.
- Verify the impact of the increased executive compensation on the company's operating expenses for the 2019 fiscal year.
- Confirm the stock price performance relative to the $36.75 exercise price of the newly granted options.
- Consult the referenced 2017 Form 10-K and Q1 2018 Form 10-Q for a comprehensive list of risk factors applicable to the company.